Journal of Bioequivalence & Bioavailability

Halabe Emilia K

Publications

• Research Article
  Single-Dose Bioequivalence of a New Fixed-Dose Combination Tablet Containing Tenofovir Disoproxil Fumarate and Lamivudine
  Author(s): Feleder Ethel C, Yerino Gustavo A, Halabe Emilia K, Carla Serebrinsky, Soledad Gonzalez and Zini ElviraFeleder Ethel C, Yerino Gustavo A, Halabe Emilia K, Carla Serebrinsky, Soledad Gonzalez and Zini Elvira
  
  Tenofovir Disoproxil Fumarate, CAS 147127-20-6 is a nucleotide reverse transcriptase inhibitor with potent activity against both HIV and hepatitis B infections. Lamivudine, CAS 134678-17-4 is a nucleoside analogue reverse transcriptase inhibitor developed as a treatment for HIV infection and also with activity against hepatitis B virus. The combination of tenofovir and lamivudine associated either with non-nucleoside reverse transcriptase inhibitors or with a ritonavir-boosted or unboosted protease inhibitor are recommended as preferred regimens for antiretroviral therapy-naïve patients infected with HIV, and also for the treatment of HIV-HVB coinfected patients. The objective of this study was to compare rate and extent of absorption and to assess the bioequivalence between a new pharmaceutical equivalent tablet formulation containing a fixed-dose combination of tenofovir disopr.. View More»
  DOI: 10.4172/jbb.1000093

  Abstract PDF